Press Releases

Press Releases

Samsung Biologics signed supply contract with Saint-Gobain

Samsung Biologics signed supply contract with Saint-Gobain


 

Samsung Biologics and Saint Gobain Strategic Collaboration & Partnership
 


- Signed a supply contract for the single-use system products with Saint-Gobain
- “Enhancing CDMO capabilities by stabilizing supply chain”

 


2018. 12. 05(wed)

 

Taehan Kim, the CEO of Samsung Biologics and Laurent Guillot, the CEO of HIGH-PERFORMANCE Materials Division, Saint Gobain 

Photo: Taehan Kim, the CEO of Samsung Biologics and Laurent Guillot, the CEO of HIGH-PERFORMANCE Materials Division, Saint Gobain

 

Incheon, South Korea, December 5th, Samsung Biologics announced today that the company signed the supply contract for single-use system products with Saint-Gobain, a French based global company, at Samsung Biologics’ headquarter in Songdo on Tuesday December 4th.

 

According to the agreement, Saint-Gobain will supply a maximum of 160 kinds of single-use system products, including tubing, filter, and hose for the biopharmaceutical production of Samsung Biologics.

 

Samsung Biologics has been used single-use system products for the small volume production. Because the single-use systems were supplied from over sea, it took long time for imports and custom clearance. Through this contract, domestic supply of single-use systems became possible, shortening the procurement period from four months to one month.
 
Samsung Biologics has negotiated supply of single-use system products with Saint-Gobain, which notably provides high-performance products and services for the Life Sciences market, from April 2018. Saint-Gobain decided to establish a production facility based at Songdo in September and the final supply contract was concluded. Construction of the facility will be completed in 2020. 

 

Songdo, where Samsung Biologics and Celltrion is located, became the largest biopharmaceutical manufacturing city with 560K liters of bioreactor capacity upon the completion of Samsung Biologics’ Plant 3. 

 

“Through partnership with Samsung Biologics, Saint-Gobain is strengthening its customer-centric development and supply chain capabilities to better serve the biopharmaceutical and medical industries in Korea. We are excited to play a key role in the advancement of the bio cluster ecosystem in Korea”, said Laurent Guillot, Senior Vice President of Saint-Gobain, CEO of High Performance Solutions.

 

Tae Han Kim, the president and CEO of Samsung Biologics, said "Samsung Biologics will gain more competitiveness in order to supply its products to customers faster and at lower prices with customized bio fluid systems that is flexible according to products." He added "Samsung Biologics, as the world's leading CMO, will continue to lead the growth of Songdo Bio-Cluster in the future for the development of Korea bio-industry."

Samsung Biologics signed supply contract with Saint-Gobain


 

201812584351138.jpg
 


- Signed a supply contract for the single-use system products with Saint-Gobain
- “Enhancing CDMO capabilities by stabilizing supply chain”

 


2018. 12. 05(wed)

 

Taehan Kim, the CEO of Samsung Biologics and Laurent Guillot, the CEO of HIGH-PERFORMANCE Materials Division, Saint Gobain 

Photo: Taehan Kim, the CEO of Samsung Biologics and Laurent Guillot, the CEO of HIGH-PERFORMANCE Materials Division, Saint Gobain

 

Incheon, South Korea, December 5th, Samsung Biologics announced today that the company signed the supply contract for single-use system products with Saint-Gobain, a French based global company, at Samsung Biologics’ headquarter in Songdo on Tuesday December 4th.

 

According to the agreement, Saint-Gobain will supply a maximum of 160 kinds of single-use system products, including tubing, filter, and hose for the biopharmaceutical production of Samsung Biologics.

 

Samsung Biologics has been used single-use system products for the small volume production. Because the single-use systems were supplied from over sea, it took long time for imports and custom clearance. Through this contract, domestic supply of single-use systems became possible, shortening the procurement period from four months to one month. 
 
Samsung Biologics has negotiated supply of single-use system products with Saint-Gobain, which notably provides high-performance products and services for the Life Sciences market, from April 2018. Saint-Gobain decided to establish a production facility based at Songdo in September and the final supply contract was concluded. Construction of the facility will be completed in 2020. 

 

Songdo, where Samsung Biologics and Celltrion is located, became the largest biopharmaceutical manufacturing city with 560K liters of bioreactor capacity upon the completion of Samsung Biologics’ Plant 3. 

 

“Through partnership with Samsung Biologics, Saint-Gobain is strengthening its customer-centric development and supply chain capabilities to better serve the biopharmaceutical and medical industries in Korea. We are excited to play a key role in the advancement of the bio cluster ecosystem in Korea”, said Laurent Guillot, Senior Vice President of Saint-Gobain, CEO of High Performance Solutions.

 

Tae Han Kim, the president and CEO of Samsung Biologics, said "Samsung Biologics will gain more competitiveness in order to supply its products to customers faster and at lower prices with customized bio fluid systems that is flexible according to products." He added "Samsung Biologics, as the world's leading CMO, will continue to lead the growth of Songdo Bio-Cluster in the future for the development of Korea bio-industry."

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION